Efficacy and Safety of Pirfenidone in CTD-ILD

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months. The clinical dyspnea score, 6-minute walking distance, index of lung function and imaging indicators are evaluated, as well as primary disease activity and adverse reactions of therapy with glucocorticoid and immunosuppressants up to 24 months.
Epistemonikos ID: 32c47e3233d7f9fc2f90ffba9bda964c96ce8575
First added on: May 13, 2024